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A B S T R A C T
Purpose
This final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple
Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether
the overall survival (OS) benefit with bortezomib-melphalan-prednisone (VMP) versus melphalan-
prednisone (MP) in patients with myeloma who were ineligible for transplantation was maintained
after 5 years of follow-up and to explore the risk of second primary malignancies.
Patients and Methods
In all, 682 patients received up to nine 6-week cycles of VMP or MP and were then observed every
12 weeks or less. Data on second primary malignancies were collected by individual patient
inquiries at all sites from 655 patients.
Results
After median follow-up of 60.1 months (range, 0 to 74 months), there was a 31% reduced risk of
death with VMP versus MP (hazard ratio [HR], 0.695; P  .001; median OS 56.4 v 43.1 months).
OS benefit with VMP was seen across prespecified patient subgroups (age  75 years, stage III
myeloma, creatinine clearance 60 mL/min). Sixty-three percent of VMP patients and 73% of MP
patients had received subsequent therapy. Time to next therapy (median, 30.7 v 20.5 months; HR,
0.557; P  .001) was longer with VMP than with MP. Among patients who received subsequent
therapies, survival from start of subsequent therapy was similar following VMP (median, 28.1
months) or MP (median, 26.8 months; HR, 0.914). Following VMP/MP, incidence proportions of
hematologic malignancies (1%/1%) and solid tumors (5%/3%) and exposure-adjusted incidence
rates (0.017/0.013 per patient-year) were similar and were consistent with background rates.
Conclusion
VMP resulted in a significant reduction in risk of death versus MP that was maintained after 5
years’ follow-up and despite substantial use of novel-agent-based salvage therapies. There is no
emerging safety signal for second primary malignancies following VMP.
J Clin Oncol 31:448-455. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Prolonging overall survival (OS) remains the ulti-
mate goal of treatment formultiplemyeloma (MM)
in the absence of curative therapy.1,2 However, par-
ticularly for regimens in the first-line setting, dem-
onstrating improved OS is challenging because of
the availability of multiple highly active treatment
options for subsequent therapy on relapse or pro-
gression.3,4 Population-based analyses have demon-
strated that median OS has improved over the past
two decades, and it has been associated with the use
of autologous stem-cell transplantation for younger
patients and the use of novel agents such as bort-
ezomib, thalidomide, and lenalidomide.5-9 Notably,
some phase III trials in patients ineligible for
transplantation10-20 have reported prolonged OS
with regimensbasedonnovel agents versusprevious
standardsof care.13,14,19A frequent criticismof stud-
ies showing positive results with experimental treat-
ments is that data are preliminary, notably for OS.
This is of particular relevance in MM, for which it
could be argued that conventional, less-expensive
first-line treatment followed by optimized rescue
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therapiesmay prove equivalent to the first-line use of novel regimens.
Thus, confirmation of benefit after long-term follow-up is essential.
Another important issue is the riskof developing secondprimary
malignancies because patients are living longer from time of diagno-
sis.21 Population studies22-25 anddata from theNationalCancer Insti-
tute’s Surveillance, Epidemiology, andEndResults (SEER)Program26
have shown that patients withMMhave an increased risk of develop-
ing specific second primary malignancies following their initial diag-
nosis, most notably, acute myeloid leukemia,26 associated either with
the disease itself or with the use of some specific agents.20,24,27-34 As
demonstratedby SEERdata, the risk of developing thesemalignancies
may increase with time from diagnosis.26 Clearly, this issue is of in-
creasing importance for patients withMM, particularly in the context
of prolonged OS.
Per protocol, we conducted a final updated OS analysis of the
international, phase IIIVISTA trial (VelcadeAs Initial StandardTher-
apy in Multiple Myeloma: Assessment With Melphalan and Predni-
sone) after a median follow-up of 5 years. VISTA compared efficacy
and safety of bortezomib-melphalan-prednisone (VMP) with
melphalan-prednisone (MP) in previously untreated patients with
MMwhowere ineligible for transplantation.To thebestofourknowl-
edge, this report represents the longest median follow-up in phase III
trials of novel agents in combination with MP in this population.10-
18,20 Data from the initial analysis, with median follow-up of 16.3
months, showed that VMPwas superior toMP across all efficacy end
points, including response rates, time toprogression (TTP), andOS.11
Anupdated analysis,withmedian follow-upof approximately 3 years,
demonstrated a continued significant OS benefit with VMP.10 This
final analysis was therefore conducted to determine whether the sig-
nificantOS benefit wasmaintained after 5 years, after extensive use of
subsequent therapiesbasedonnovel agentsas salvage therapies, and to
explore for the first time the risk of second primarymalignancies with
long-term use of bortezomib in VMP.
PATIENTS AND METHODS
Patients and Study Design
VISTA study details have been reported.10,11 Briefly, 682 patients with
previously untreated MM who were ineligible for high-dose therapy were
enrolled at 151 sites in22 countries inEurope,NorthAmerica, SouthAmerica,
andAsia. Eligible patients were age 18 years and had symptomatic,measur-
able disease; exclusion criteria included grade 2 peripheral neuropathy or
neuropathic pain and a serum creatinine level of more than 2 mg/dL. Review
boards at all participating institutions approved the study, which was con-
ducted according to International Conference on Harmonization Guidelines
for Good Clinical Practice. All patients provided written informed consent.
Patients were randomly assigned 1:1 to receive nine 6-week cycles of
VMP (n 344; bortezomib 1.3 mg/m2 per day on days 1, 4, 8, 11, 22, 25, 29,
and32duringcycles 1 to4andondays1, 8, 22, and29duringcycles 5 to9,with
melphalan 9mg/m2 and prednisone 60mg/m2 per day on days 1 through 4 of
all cycles) orMP alone (n 338). The primary end pointwas TTP. Secondary
end points included response rates, OS, and safety/tolerability; additional end
points included time tonext therapy (TTNT; fromrandomassignment to start
of subsequent anti-MMtreatment) and treatment-free interval (TFI; from the
last dose of study drug to the start of subsequent treatment). Response and
progression were assessed according to European Group for Blood and Bone
Marrow Transplantation (EBMT) criteria35 by using central laboratory
M-protein assessment. Central laboratory assessment was stopped following
the third preplanned interim analysis10,11; consequently response, TTP, and
progression-free survival (PFS) data could not be updated beyond this initial
report (median follow-up, 16.3 months) according to the same stringency
because centralizedM-protein assessment was no longer available.
Per protocol, patients were observed at least every 12 weeks for up to 4.5
years after the last-patient-in date for survival and subsequent therapy; data
cutoff was March 24, 2011. Data on second primary malignancies were col-
lected by individual patient inquiries at all study sites during February 2011
from 655 patients (96%).
Statistical Analysis
OS was analyzed by using Kaplan-Meier methodology, and TTNT and
TFI were analyzed by using cumulative incidence methodology. Data were
compared between arms by using stratified log-rank tests, and hazard ratios
(HRs) with 95% CIs were calculated. OS was compared between arms and
within arms inprespecifiedpatient subgroupsdefinedby age, sex, race, region,
baseline 2-microglobulin, baseline albumin, International Staging System
(ISS)disease stage,36 and renal function.OSwas also evaluated inpatientswith
documented high-risk cytogenetics such as t(4;14), t(14;16), and del(17p).OS
was compared according to best response (by EBMT criteria), overall and by
treatment arm, by using multivariate Cox regression with time-dependent
covariates that incorporated response, with adjustment for baseline 2-
microglobulin, baseline albumin, and region as stratification factors, plus age,
sex, race, type ofMM, baseline Karnofsky performance status, and number of
bone lesions at baseline as covariates.OS and survival fromstart of subsequent
therapywerealsoevaluated inpatientswhohadreceived subsequent therapies,
and OS was compared between all patients on the VMP arm and patients on
the MP arm who had not yet relapsed, received salvage therapy with bort-
ezomib, or died without receiving subsequent therapy.
For analyses of secondprimarymalignancies, incidenceproportions and
exposure-adjusted incidence rates were calculated, plus relative risks and 95%
CIs. Exposure was defined as total duration of follow-up in each patient from
start of treatment to the time of reporting occurrence of second primary
malignancy. Incidence rate was calculated by dividing total number of second
primary malignancies by duration of exposure in patient-years.
RESULTS
Patients
Baseline characteristics have been reported11 and were well bal-
ancedbetween treatment arms.Overall,medianagewas71years, 30%
ofpatientswere age75years, and34%had ISS stage IIIMM.Atdata
cutoff, only 16 patients (5%) in each arm had been lost to follow-up
(Fig 1).
OS
After a median follow-up of 5 years (60.1 months; range, 0 to 74
months) from random assignment, 176 patients (51%) randomly
assigned to VMP and 211 (62%) randomly assigned to MP had died
(Fig 1). There was a 31% reduced risk of death following VMP versus
MP (HR, 0.695; P  .001; Fig 2). Median OS was 56.4 versus 43.1
months; 5-year OS rates were 46.0% (95% CI, 40.3% to 51.8%) and
34.4% (95%CI, 28.9% to 39.9%), respectively.
The OS benefit with VMP was seen across prespecified patient
subgroups, including those age  75 years (median, 50.7 v 32.9
months; HR, 0.70), those younger than 75 years (median, 58.6 v
47.7months; HR, 0.69), patients with ISS stage IIIMM (median, 46.2
v30.5months;HR,0.63), and thosewith creatinine clearance less than
60 mL/min (median, 56.8 v 36.7 months; HR, 0.70; Fig 3). However,
no significant difference was observed in the small subgroup with
documented high-risk cytogenetics (n  46; Fig 3); because of low
patient numbers, additional analyses by individual cytogenetic abnor-
malities were not feasible.
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Multivariate Cox regression analysis of OS according to best
response demonstrated a clear impact of response on improved out-
come. OS was significantly improved with complete response versus
less-than-complete response by intent-to-treat analysis (HR, 0.675;
95% CI, 0.486 to 0.936; P  .0184; VMP arm: HR, 0.708; 95% CI,
0.484 to 1.036;P .0755;MParm:HR, 0.710; 95%CI, 0.303 to 1.662;
P .4301).Therewasalsoa trend toward improvedOSwithcomplete
versus partial response by intent-to-treat analysis (HR, 0.761; 95%CI,
0.540 to 1.071; P .1173).
Subsequent Therapies and TTNT
In all, 215 (63%) of 344VMP and 246 (73%) of 338MPpatients
had received subsequent anti-MM therapies. Use of subsequent tha-
lidomide or lenalidomide was similar between arms, with 103 (30%)
of 344 VMP patients and 122 (36%) of 338 MP patients having
received subsequent thalidomide and 84 (24%) and 63 (19%) subse-
quent lenalidomide (Appendix Table A1, online only). A lower pro-
portion of VMP versus MP patients received subsequent bortezomib
(22%[n 77] versus 43%[n 145]); this imbalancewas also seen in
the small subgroup of patients with high-risk cytogenetics (Appendix
Table A1). Investigator-assessed response rates to subsequent bort-
ezomib and/or bortezomib-containing regimens were 50% following
VMP(ie,bortezomibre-treatment)and58%followingMP,were46%
and 55%, respectively, to subsequent thalidomide and/or thalido-
mide-containing regimens, and were 62% and 56%, respectively, to
subsequent lenalidomide and/or lenalidomide-containing regimens.
Assessed for eligibility
(N = 755)
Randomly allocated
(n = 682)
Allocated to bortezomib plus (n = 344) 
  melphalan–prednisone
Received treatment (n = 340)
Did not receive treatment (n = 4)
)3 = n( eciohc tneitaP  
)1 = n( rehtO  
Allocated to melphalan–prednisone (n = 338)
Received treatment (n = 337)
Did not receive treatment (n = 1)
  Adverse event (renal insufficiency) (n = 1)
Trial discontinued (n = 340)
  Study closed by sponsor (n = 133)
)671 = n( htaeD  
)51 = n( eciohc tneitaP  
)61 = n( pu-wollof ot tsoL  
Trial discontinued (n = 337)
  Study closed by sponsor (n = 95)
)112 = n( htaeD  
)51 = n( eciohc tneitaP  
)61 = n( pu-wollof ot tsoL  
Treatment completed (n = 199)
Discontinued treatment (n = 141)
  Progressive disease (n = 24)
)25 = n( tneve esrevdA  
)23 = n( eciohc tneitaP  
)41 = n( htaeD  
  Maintenance of complete response (n = 9)
)01 = n( rehtO  
Treatment completed (n = 169)
Discontinued treatment (n = 168)
  Progressive disease (n = 73)
)84 = n( tneve esrevdA  
)91 = n( eciohc tneitaP  
)71 = n( htaeD  
  Maintenance of complete response (n = 1)
)01 = n( rehtO  
Analyzed for response (n = 337)
Excluded from response analysis (n = 3)
  No measurable disease at baseline (n = 3)
Analyzed for response (n = 331)
Excluded from response analysis (n = 6)
  No measurable disease at baseline (n = 6)
Analyzed for SPMs (n = 327)
Excluded from SPM analysis (n = 13)
)31 = n( pu-wollof ot tsoL  
Analyzed for SPMs (n = 328)
Excluded from SPM analysis (n = 9)
)9 = n( pu-wollof ot tsoL  
Received subsequent therapy (n = 215)
Did not receive subsequent therapy (n = 129)
  Not yet required (n = 120)
  Died due to PD prior to receiving (n = 9) 
    subsequent therapy
Received subsequent therapy (n = 246)
Did not receive subsequent therapy (n = 92)
)87 = n( deriuqer tey toN  
  Died due to PD prior to receiving 
    subsequent therapy (n = 14)
Excluded
(n = 73)
Fig 1. Updated CONSORT diagram
showing patient flow through the study.
PD, progressive disease; SPM, second
primary malignancy.
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Use of older agents was generally similar between arms (Appendix
Table A1). TTNT (median, 30.7 v 20.5 months; HR, 0.557; P .001)
andTFI (median, 19.4 v 9.1months;HR, 0.573;P .001)were longer
with VMP versusMP by cumulative incidence analysis (Table 1).
To assess whether VMP induced more resistant relapses, we
compared survival from start of subsequent therapy and showed that
itwas similar between arms (HR, 0.914; 95%CI, 0.719 to 1.163; Fig 4).
Moreover, to investigate the treatment paradigm of first-line MP
followed by subsequent salvage bortezomib, we compared OS in all
VMP patients with OS in MP patients who had received salvage
therapywith bortezomib (n 145), not yet relapsed (n 78), or died
without receiving subsequent therapy (n 14). Median OS was 56.4
versus 45.4 months, respectively (HR, 0.714; 95% CI, 0.571 to 0.892;
P .0029). Similar results were observed in an analysis incorporating
MPpatients who received bortezomib at first relapse only (HR, 0.638;
95%CI, 0.499 to 0.817; P .001).
Second Primary Malignancies
In all, 327VMPpatients (95%) and 328MPpatients (97%)were
included in the analyses of second primary malignancies (Table 2).
Incidence proportions of all malignancies and of fatal hematologic
malignancies and solid tumors were similar between arms (Table 2).
Nineteen (6%) of 327 patients in the VMP arm and 13 (4%) of 328
patients in theMP arm reported second primarymalignancies. Three
patients (1%) ineacharmhadhematologicmalignancies: twopatients
in eacharmhadacutemyeloid leukemia (fatal in all fourpatients), one
patient in the MP arm had B-cell non-Hodgkin lymphoma that was
fatal, andonepatient in theVMParmhadmyelodysplastic syndrome.
In theVMParm, these hematologicmalignancieswere reported at 18,
47.4, and 48 months after the start of treatment; in the MP arm, the
malignancies occurred at 1, 8.8, and 35months. Sixteen patients (5%)
in the VMP arm and 10 patients (3%) in the MP arm had second
primary nonhematologic malignancies that were mostly gastrointes-
tinal (five, VMP; four, MP) and renal or prostate (four, VMP; three,
MP) tumors. These were fatal in six patients (2%) in each arm. These
malignancies occurred after a median of 22.7 months (range, 1 to 56
naideM n/stnevE naideM n/stnevE IC %59 etamitsE puorG
Age, years
6.85 732/311 7.74 732/631 98.0 ot 35.0 96.0 57 <  
  ≥ 7.05 701/36 9.23 101/57 10.1 ot 94.0 07.0 57  
Sex
6.55 571/59 7.63 661/901 78.0 ot 94.0 66.0 elaM  
6.06 961/18 4.64 271/201 10.1 ot 65.0 57.0 elameF   
Race
9.65 403/451 0.54 592/971 49.0 ot 06.0 57.0 etihW  
8.05 33/91 2.71 63/82 19.0 ot 42.0 74.0 naisA  
AN 7/3 8.13 7/4 59.5 ot 60.0 06.0 rehtO   
ß2 microglobulin, mg/dL
AN 04/01 1.76 93/71 23.1 ot 62.0 95.0 5.2 <  
4.65 091/99 5.64 781/011 20.1 ot 95.0 77.0 5.5–5.2  
7.34 411/76 5.03 211/48 78.0 ot 54.0 36.0 5.5 >   
Albumin, g/dL
8.05 002/811 8.43 902/841 48.0 ot 15.0 56.0 5.3 <  
  ≥ AN 241/65 4.95 821/26 60.1 ot 15.0 37.0 5.3  
Region
9.55 23/91 4.64 03/71 01.2 ot 55.0 70.1 aciremA htroN  
8.65 372/631 0.54 562/161 98.0 ot 65.0 17.0 eporuE  
6.55 93/12 6.32 34/33 77.0 ot 32.0 24.0 rehtO   
ISS stage
AN 46/02 AN 46/52 54.1 ot 44.0 97.0 I  
6.55 161/88 3.34 951/101 00.1 ot 65.0 57.0 II  
2.64 911/86 5.03 511/58 78.0 ot 54.0 36.0 III   
Creatinine clearance, mL/min
  ≥ 6.55 951/38 7.25 451/09 00.1 ot 35.0 37.0 06 
8.65 581/39 7.63 481/121 29.0 ot 35.0 96.0 06 <   
Cytogen risk
2.85 241/56 3.84 341/67 39.0 ot 64.0 56.0 dradnatS  
1.44 62/71 6.05 02/31 14.2 ot 03.0 58.0 hgiH  
MP VMP
0.04 0.09 0.20 0.45
HR (log scale)
1.00 2.23 4.95
Fig 3. Subgroup analyses of overall survival.
P values for subgroup interaction tests were
all nonsignificant (range, .1394 [region: other]
to .9352 [age:  75 years]). HR, hazard ratio;
ISS, International Staging System; MP, mel-
phalan-prednisone; NA, not assessable; VMP,
bortezomib-melphalan-prednisone.
No. at risk
MP 338 301 262 240 216 196 168 153 133 112 61 24 3
VMP 344 300 288 270 246 232 216 199 176 158 78 34 1
0
Group n Event Median HR (95% CI)     P    
MP 338 211 43.1
VMP 344 176 56.4 0.695 (0.567 to 0.852) < .001
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Fig 2. Overall survival (intent-to-treat analysis) in patients randomly assigned to
bortezomib-melphalan-prednisone (VMP) or melphalan-prednisone (MP) after a
median follow-up of 5 years. HR, hazard ratio.
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months) in theVMParmand 30.3months (range, 3 to 63months) in
theMP arm.
The overall observation or exposure period for recording occur-
rence of second primary malignancies was asymmetric, being longer
in the VMP arm compared with the MP arm because more patients
remained alive for a longer period on that arm. Exposure in the VMP
arm was greater than in the MP arm by 163 patient-years (1,167 v
1,004 patient-years, respectively; Table 2). The exposure-adjusted in-
cidence rates for all second primary malignancies, which take into
account this longer observation period, were similar between arms
(0.0166 and 0.013 per patient-year for VMP andMP, respectively).
DISCUSSION
The findings of this final analysis of the VISTA phase III trial demon-
strate a persistent significant OS benefit with VMP versus MP. These
data are highly robust because of the large patient population and
lengthy follow-up and show that VMP resulted in a substantial long-
termOSbenefit versusMP,witha13.3-month increase in themedian.
This benefit compares favorably with the 6.6-month increase in me-
dianOS (39.3 v 32.7months) reported in ameta-analysis of six phase
III trials ofMP plus thalidomide (MPT) versusMP.19 TheHR for OS
in this meta-analysis was 0.83 (95% CI, 0.73 to 0.94; P  .004),
representing a 17% reduced risk of death withMPT19 comparedwith
the 31% reduced risk of death with VMP versus MP reported here.
Notably, the median follow-up in seven individual studies of MPT
versus MP ranges from 23 to 51.5 months,12-18 compared with the
60.1-month follow-up for the analysis reported here. In addition, it
should be noted that the OS benefit observed in this trial was not due
to a poor outcome with MP, since median OS with MP in this trial
(43.1 months) was longer than median OS withMP in theMPT trial
meta-analysis (32.7 months). The median OS observed with VMP
(56.4 months) appears similar to that previously reported after long-
term follow-up from studies of high-dose therapy and autologous
stem-cell transplantation conducted in the 1990s and early 2000s
(median, 4.0 to 5.7 years)37; however, as reviewed recently, it should
be noted that results from transplantation studies have also signifi-
cantly improved in the past decade with the combination of novel
drugs (median of approximately 7 to 10 years).37
Importantly, theOSbenefitwithVMPversusMPwas seenacross
multiple prespecified patient subgroups, including similar benefit in
elderly (age 75 years) and younger patients, and the HR in favor of
VMP was generally consistent with that for the overall population,
Table 1. TTNT in Patients Randomly Assigned to VMP or MP and TFI in the Treated Population, Analyzed by Cumulative Incidence Using the Competing
Risk Approach
Variable
TTNT TFI
VMP
(n  344)
MP
(n  338)
VMP
(n  340)
MP
(n  337)
No. % HR 95% CI P† No. % 95% CI No. % HR 95% CI P† No. % 95% CI
Events 224 65 260 77 224 66 260 77
Censored/competing
events 120 35 78 23 116 34 77 23
TTNT/TFI, months
25% quartile‡ 17.1 10.0 7.1 2.2
50% quartile‡ 30.7 20.5 19.4 9.1
75% quartile‡ N/E 34.8 52.7 24.1
Event-free
survival rate‡ 0.557 0.462 to 0.671  .001 0.573 0.476 to 0.690  .001
1 year 85.1 81.1 to 88.7 71.3 66.3 to 76.1 62.0 56.8 to 67.3 44.1 38.9 to 49.7
2 year 60.5 55.3 to 65.8 40.9 35.7 to 46.5 46.3 41.1 to 51.9 25.1 20.7 to 30.3
3 year 45.2 40.0 to 50.8 24.4 20.0 to 29.5 36.1 31.1 to 41.6 19.4 15.5 to 24.2
4 year 35.7 30.7 to 41.2 19.6 15.6 to 24.5 30.9 26.0 to 36.5 18.1 14.2 to 22.9
5 year 31.5 26.6 to 37.0 18.3 14.4 to 23.2 25.9 20.4 to 32.4 15.6 10.5 to 22.9
Abbreviations: HR, hazard ratio; MP, melphalan-prednisone; N/E, not estimable; TFI, treatment-free interval; TTNT, time to next therapy; VMP, bortezomib-
melphalan-prednisone.
Based on the cause-specific hazard.
†Based on a stratified log-rank test comparing cause-specific hazards for subsequent treatment.
‡Based on cumulative incidence estimates.
No. at risk
MP 246 194 158 135 116 91 68 39 25 14 5 1
VMP 215 175 143 121 94 75 48 27 12 6 3 0
0
Group n Event Median         HR (95% CI)        
MP 246 161 26.8
VMP 215 122 28.1 0.914 (0.719 to 1.163)
Ev
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al
 (%
)
Time (months)
100
80
60
40
20
6 12 18 24 30 36 42 48 54 60 66 72
Fig 4. Analysis of survival from start of subsequent therapy in all randomly
assigned patients who received subsequent therapy. HR, hazard ratio; MP,
melphalan-prednisone; VMP, bortezomib-melphalan-prednisone.
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indicating the applicability of these findings to the broad MM popu-
lation. However, there was an absence of OS benefit among the small
subgroup of patients with documented high-risk cytogenetics (Fig 3),
whereas bortezomib-based therapy has previously been shown to
result in high response rates and promising long-term outcomes in
suchpatients.10,11,38-47 The limited sample size prevents anymeaning-
ful conclusions from being drawn.
As reported for the previous analysis of VISTA,10 VMP contin-
ued to provide a significant clinical benefit versus MP in terms of
prolonged TTNT and TFI. TTP and PFS could not be updated at this
final analysis because they were based on central laboratory assess-
ment and, because of the highly significant initial benefit observed for
these end points,11 it was decided to stop central assessment following
the initial analysis.
Survival from the start of subsequent therapy was similar
between arms, indicating that VMP did not induce more resistant
relapses. This finding is particularly notable because this analysis
contained a bias in favor of MP-treated patients, because it ex-
cluded a higher proportion of VMP-treated patients who experi-
enced most benefit (ie, those who had not yet required subsequent
therapy and were thus most sensitive to therapy or had better
prognosis). In addition, OS with VMP was significantly longer
versus the treatment paradigm of first-lineMP followed by salvage
bortezomib (ie, MP patients who did receive, or could have re-
ceived, bortezomib at relapse). Overall, these findings demonstrate
the importance of a treatment paradigm of providing optimal
first-line treatment, rather than reserving novel agents for sal-
vage therapy.
To the best of our knowledge, this is the first paper reporting the
incidence of second primary malignancies with bortezomib-based
treatment. It is important to highlight that less than 5% of patients
were lost to follow-up.With this thorough data collection, we identi-
fied no increased risk of second primary malignancies with VMP
versus MP. Importantly, overall incidence rates in both arms (VMP,
0.017 andMP, 0.0130per patient-year)were consistentwith the back-
ground incidence rate of 0.019 for all cancers in the general US popu-
lation age 65 to 74 years, as reported for 2004 to 2008 by the SEER
Program.48 These data indicate that use of bortezomib for up to
approximately 1 year does not add to the previously reported leuke-
mogenic effectofmelphalan,24,27,29with the incidence ratesof second-
ary hematologic malignancies low and similar in both the VMP and
MP arms. Addition of lenalidomide to MP and use of maintenance
lenalidomide until progression (median PFS, 31 months) has been
suggested to result in a small increased risk of secondary leukemia
compared with MP alone, although this may be associated with the
presence of complex cytogenetics at baseline.20 However, the in-
creased risk of secondary malignancies with lenalidomide mainte-
nance, which has also been shown post-transplantation,28,31 is
counterbalanced by the highly significant PFS benefit demon-
strated,20,28,31 together with an OS benefit in one study.31 Moreover,
incidence rates were low, with no increase seen, in another study of
lenalidomide-based therapy in the first-line setting.34
In conclusion, initial treatment of patients with MM who are
ineligible for transplantation with VMP results in a significant reduc-
tion in the risk of death comparedwith initial treatmentwithMP that
is maintained after 5 years of follow-up and despite substantial use of
salvage therapiesbasedonnovel agents. Furthermore, our exploratory
analysis identified no emerging safety signal for second primary ma-
lignancies following treatment with VMP.
Table 2. Incidence Proportion and Exposure-Adjusted Incidence Rate in Patient-Years of Second Primary Malignancies Following Treatment With VMP and MP
Second Primary Malignancy
VMP MP
RR 95% CINo. % No. %
Patients with data collected 327 328
Hematologic 3 1 3 1 1.003 0.204 to 4.933
Acute myeloid leukemia 2 1 2 1
B-cell lymphoma 0 1  1
Myelodysplastic syndromes 1†  1 0
Fatal hematologic 2 1 3 1 0.669 0.113 to 3.976
Nonhematologic 16 5 10 3 1.605 0.739 to 3.484
GI 5† 2 4 1
Renal/prostate 4† 1 3† 1
Respiratory 2† 1 0
Skin 2† 1 0
Other 3† 1 3† 1
Fatal nonhematologic 6 2 6 2 1.003 0.327 to 3.078
Patient-years for which data collected 1,167 1,004
Hematologic per patient-year‡ 0.0026 0.0030 0.862 0.174 to 4.269
Fatal 0.0017 0.0030 0.574 0.096 to 3.436
Nonhematologic per patient-year‡ 0.0140 0.0100 1.389 0.630 to 3.061
Fatal 0.0052 0.0060 0.859 0.277 to 2.664
Overall per patient-year‡ 0.0166 0.0130
Abbreviations: MP, melphalan-prednisone; RR, relative risk; VMP, bortezomib-melphalan-prednisone.
RR  1 favors VMP.
†Nonfatal malignancies, including one myelodysplastic syndrome on VMP arm, three GI on VMP arm, two renal/prostate on each arm, one respiratory on VMP arm,
two skin on VMP arm, and two “other” on each arm.
‡Incidence rate.
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